Page last updated: 2024-11-06

ytterbium trichloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ytterbium trichloride: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ytterbium(III) chloride : The trichloride salt of ytterbium(III). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9860484
CHEBI ID67096
MeSH IDM0130712

Synonyms (14)

Synonym
ytterbium(iii) chloride
ytterbium trichloride
ytterbium(3+) trichloride
NCGC00254964-01
tox21_301062
dtxcid8027117
cas-10361-91-8
dtxsid0047117 ,
CHEBI:67096 ,
AKOS025293997
CKLHRQNQYIJFFX-UHFFFAOYSA-K
cl3yb
SY027097
ytterbium(iii)chloride

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The inhibition was dependent on the actual amount of toxic Yb uptake by the cucumber plants."( Comparative toxicity of nanoparticulate/bulk Yb₂O₃ and YbCl₃ to cucumber (Cucumis sativus).
Chai, Z; Ding, Y; Guo, Z; He, X; Ma, Y; Tai, R; Zhang, P; Zhang, Z; Zhao, Y, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Five-hr marker excretions as a percent of that originally dosed were similar (P greater than ."( Comparison of ferric oxide and ytterbium chloride as digesta markers in broiler chicks.
Sarani, S; Smith, MO; Teeter, TG, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
NMR shift reagentIn NMR spectroscopy a reagent added to a solution to induce chemical shifts and thus simplify complex spectra.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
inorganic chloride
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency63.26090.007215.758889.3584AID1224835
AR proteinHomo sapiens (human)Potency36.65140.000221.22318,912.5098AID743036; AID743042
progesterone receptorHomo sapiens (human)Potency15.35530.000417.946075.1148AID1346784
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency4.89660.000214.376460.0339AID720691
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency3.65740.001530.607315,848.9004AID1224849; AID1259403
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency4.89660.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency2.83630.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency3.46650.023723.228263.5986AID743223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (25.00)18.7374
1990's1 (8.33)18.2507
2000's5 (41.67)29.6817
2010's2 (16.67)24.3611
2020's1 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]